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Background. We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclo-
nal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharma-
codynamics, safety/tolerability, and preliminary clinical efficacy of the combination.
Methods. Twenty-two participants with histologically confirmed glioblastoma in first relapse were treated every 2 weeks with
RO5323441 (625 mg, 1250 mg, or 2500 mg) plus bevacizumab (10 mg/kg). A standard 3+ 3 dose-escalation trial design was
used.
Results. RO5323441 combined with bevacizumab was generally well tolerated, and the maximum tolerated dose was not
reached. Two participants experienced dose-limiting toxicities (grade 3 meningitis associated with spinal fluid leak [1250 mg]
and grade 3 cerebral infarction [2500 mg]). Common adverse events included hypertension (14 participants, 64%), headache
(12 participants, 55%), dysphonia (11 participants, 50%) and fatigue (6 participants, 27%).The pharmacokinetics of
RO5323441 were linear, over-the-dose range, and bevacizumab exposure was unaffected by RO5323441 coadministration. Mod-
ulation of plasmatic angiogenic proteins, with increases in VEGFA and decreases in FLT4, was observed. Dynamic contrast-
enhanced/diffusion-weighted MRI revealed large decreases in vascular parameters that were maintained through the dosing
period. Combination therapy achieved an overall response rate of 22.7%, including one complete response, and median progres-
sion-free and overall survival of 3.5 and 8.5 months, respectively.
Conclusion. The toxicity profile of RO5323441 plus bevacizumab was acceptable andmanageable. The observed clinical activity of
the combination does not appear to improve on that obtained with single-agent bevacizumab in patients with recurrent
glioblastoma.
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Tumor angiogenesis is a fundamental step in carcinogenesis,1
and the vascular endothelial growth factor (VEGF) family of gly-
coproteins (VEGFA–D [P1GF] and placental growth factor [PGF/
PlGF]) are central to this process.2,3 PlGF is a pleiotropic, proan-
giogenic growth factor that can stimulate tumor angiogenesis
directly by affecting endothelial cells, pericytes, and smooth
muscle cells as well as indirectly by enhancing VEGF-driven an-
giogenesis and by attracting proangiogenic myeloid cells.4 PlGF
expression is increased in some tumor types and can correlate
with tumor stage and poor outcomes, including disease pro-
gression and reduced survival.5–7
Glioblastoma is the most aggressive malignant primary
brain tumor in adults and is a primary target for antiangiogenic
therapy due to the high degree of vascularization.8,9 Several
VEGF pathway-targeting drugs have emerged including cedira-
nib, aflibercept, and the anti-VEGF monoclonal antibody
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bevacizumab, which is both active and well tolerated in pa-
tients with glioblastoma. Based on the durable objective re-
sponse rates (ORRs) demonstrated in two phase 2 trials10,11
in 2009, the US Food and Drug Administration granted acceler-
ated approval of single-agent bevacizumab for the treatment
of patients with progressive glioblastoma following prior thera-
py.12 However, eventual disease progression is inevitable
because of the emergence of resistance to VEGF and VEGR re-
ceptor (VEGFR/KDR)-directed therapy.13
Simultaneous blockade of multiple angiogenic pathways
might improve efficacy and reduce therapeutic resistance. Evi-
dence indicates that PlGF is upregulated in response to VEGF(R)
inhibition, supporting the development of combined therapy
that targets both VEGFA and PlGF.14,15 RO5323441 (RG7334/
TB-403) is a humanized recombinant immunoglobulin G1
(IgG1) anti-PlGF monoclonal antibody. Unlike VEGF, PlGF selec-
tively binds VEGFR1 (FLT1) and its co-receptors neuropilin-1
(NRP1) and -2 (NRP2).16 Preclinical studies have shown that
RO5323441 inhibits the growth of VEGF blockade-resistant tu-
mors without affecting healthy vessels.16 RO5323441 is also
capable of enhancing the efficacy of chemotherapy and
VEGFR inhibitors in vivo and inhibiting angiogenesis and
tumor cell motility.16,17 Single-dose RO5323441 displayed a fa-
vorable safety profile and dose-linear pharmacokinetics (PK) in
a first-in-human dose-escalation trial.18 A subsequent phase 2
study of 23 patients with advanced solid tumors showed that
RO5323441 was well tolerated up to a dose of 30 mg/kg every
3 weeks. No dose-limiting toxicities (DLTs) were reported, and
hence the maximum tolerated dose (MTD) was not reached.19
PK analysis confirmed the dose-proportional exposure of
RO5323441 with a terminal half-life of 9–14 days.
Here we report the results of a phase 1 study that investigat-
ed RO5323441 combined with bevacizumab in patients with
recurrent glioblastoma. The primary objective was to establish
the recommended dose of RO5323441 for use with beva-
cizumab. Secondary objectives included evaluation of the PK,
pharmacodynamics (PD), safety/tolerability, and preliminary
efficacy of the combination treatment.
Methods
Study Design
Study NCT01308684was a phase 1b, open-label, dose-escalation
multicenter study of RO5323441 combined with bevacizumab
in patients with recurrent glioblastoma. The study was con-
ducted at 4 centers in Switzerland, France, Denmark, and the
United Kingdom. Local ethics committee approval was ob-
tained, and all participants were able to provide their own writ-
ten informed consent. The study was conducted in accordance
with Good Clinical Practice and the Declaration of Helsinki.
From day 1, 3 fixed doses of RO5323441 (625, 1250, and
2500 mg) were administered once every 2 weeks (q2w) with
10 mg/kg bevacizumab. A standard 3+ 3 dose-escalation
study design was used to determine the MTD based on the oc-
currence of DLTs. At the MTD or top dose level (set at 2500 mg),
6 additional participants were enrolled into an expansion co-
hort to further evaluate safety/tolerability, PK, and PD. This co-
hort received pretreatment with single-agent bevacizumab
(10 mg/kg) on day 214 and day 1, single-agent RO5323441
(2500 mg) on day 22 with combination therapy given q2w
from day 15 onwards. This dosing schedule was selected to
allow us to first measure the PD effects of bevacizumab mono-
therapy, after which any additional PD effect due to combina-
tion dosing with RO5323441 could be determined. Participants
continued treatment until disease progression, unacceptable
toxicity, investigator decision, or patient refusal.
Patients
Eligible patients were ≥18 years of age with histologically con-
firmed glioblastoma in first relapse and radiographic evidence
of disease progression. Patients had already received standard
frontline radiotherapy and temozolomide (TMZ) and had a Kar-
nofsky performance status ≥70%, adequate hematological
(absolute neutrophil count ≥1 500/mL; platelets ≥100 000/mL),
and hepatic and renal function. Following radio-chemotherapy,
a minimum treatment interval of 12 weeks was required to re-
duce the likelihood of pseudoprogression. Participants receiving
corticosteroids had to be on a stable or decreasing dose for ≥5
days before a baseline MRI scan was conducted.
Exclusion criteria included previous treatment with PlGF/
VEGF(R) targeting agents, cilengitide, enzastaurin, or intracere-
bral agents; MRI evidence of recent brain hemorrhage, uncon-
trolled arterial hypertension or prior history of hypertensive
crisis/encephalopathy; prior bleeding diathesis or coagulop-
athy; major surgery and hemoptysis within 1 month; or a
history of significant cerebrovascular/cardiovascular disease,
abdominal fistula, gastrointestinal perforation, or intracranial
abscess within 6 months.
Study Drug Administration
RO5323441 and bevacizumab were administered as continu-
ous intravenous (IV) infusions. RO5323441 was administered
immediately prior to bevacizumab.
Safety Assessments
The participants were seen before each study drug administra-
tion and weekly during the first 4 weeks. Safety assessments
included physical (performance status, vital signs) and labora-
tory examinations as well as twice-daily measurement of blood
pressure for the first 4 weeks. Baseline and end-of-study as-
sessments included electrocardiograms (ECGs) and lower ex-
tremity ultrasounds. Adverse events (AEs) were defined
according to the NCI Common Terminology Criteria for AEs
(CTCAE), version 4.0.20
Definition of Dose-limiting Toxicity and Maximum
Tolerated Dose
A DLT was defined as a study drug-related CTCAE that occurred
during the first 28 days of treatment with RO5323441 plus bev-
acizumab. These included: grade (G) 4 neutropenia or thrombo-
cytopenia; G3 thrombocytopenia with bleeding; febrile
neutropenia and/or documented infection requiring IVantibiot-
ics; any nonhematological G4 event or G3 event that caused a
dosing delay of .7 days (except for G3 nausea/vomiting, diar-
rhea, and skin AEs without adequate supportive care measures);
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or any recurrence of non-DLT G3 nonhematological event.
Additional protocol-specific DLTs were G4 fistula; ≥G3 cardiac
disorder; hemorrhage or hypertension if uncontrolled with
medication; ≥G2 thromboembolic event or pulmonary hemor-
rhage; or any grade intracranial hemorrhage, gastrointestinal
perforation, tracheo-esophageal fistula, or reversible posterior
leukoencephalopathy. The MTD was defined as the dose level
below any dose level with more than one DLT.
Pharmacokinetic Assessments
For the dose-escalation part of the study, PK blood samples
were collected before and after each infusion with additional
samples obtained on days 8 and 22 (7 days after the first 2 in-
fusions). For the expansion cohort, blood was collected before
and after the infusions on days214 and 1 (bevacizumab only),
day 22 (RO5323441 only), and at all other dosing occasions
(combination treatment). Additional samples were obtained
on days 8 and 22. Except for day 214, preinfusion samples
were taken ,3 hours prior to the dynamic contrast-enhanced
(DCE)-MRI scan. Serum-free bevacizumab concentrations
were determined by ELISA using recombinant human VEGF
for capture and goat antihuman IgG conjugated to horseradish
peroxidase for detection, as described previously.21 RO5323441
quantification was performed using a sandwich ELISA with im-
mobilized biotinylated recombinant human PlGF as capture re-
agent and digoxigenylated (F(ab′)2-specific) sheep polyclonal
anti-RO5323441 antibody with horseradish peroxidase-
conjugated antidigoxigenin Fab fragments as detection re-
agents. Only RO5323441 with free and active binding sites
was detected with the analytical method.
Pharmacodynamic Assessments
For the expansion cohort only, the pharmacological effect of
RO5323441 on vascular parameters was investigated by
DCE-MRI and diffusion-weighted (DW)-MRI conducted twice
at baseline and on days 22, 1, 15, and 53–55 (Fig. 1A).
Image acquisition was performed before, during, and after
the i.v. administration of a gadolinium contrast agent while
participants were on a stable dose of steroids for at least 5
days. DCE-MRI was conducted before any study drug treatment
scheduled for the same day. Image acquisition was performed
locally, and analysis of the scans was conducted centrally.
Plasma PlGF, VEGFA, and fms-related tyrosine kinase-4
(FLT4) levels were quantified using immunological multipara-
metric chip technique (IMPACT) analysis as part of a Roche
solid phase antibody sandwich ELISA. Blood was collected on
days 1, 8, 15, 29, 53–55, 85, and every 3 months thereafter,
with additional samples on days 214 and 22 in the expansion
cohort only. For VEGFA, this assay detects both free VEGFA and
part of the bound VEGFA.
Efficacy Assessments
Tumor response was evaluated every 8 weeks using Revised As-
sessment in Neuro-Oncology (RANO) criteria,22 which combine
radiological tumor assessment with neurological assessment
while taking into account corticosteroid use. Disease imaging
was performed locally, and scans were interpreted by a single
radiologist at each site wherever possible. Best ORR, disease
control rate (DCR), median progression-free survival (PFS),
6-month PFS rate (PFS-6), and median overall survival (OS)
were calculated. DCR was defined as the rate of combined com-
plete responses, partial responses, and stable disease as as-
sessed by RANO criteria.
Statistical Considerations
All participants who received at least one dose of study medi-
cation were included in the safety and efficacy populations.
DCE-/DW-MRI parameters were evaluated using a within-
patient change from baseline. Median time-to-event for PFS
and OS was analyzed using Kaplan-Meier estimates.
Results
Participant Characteristics and Treatment
Twenty-two participants were enrolled into 3 dose groups
(Table 1). All participants had received previous TMZ treatment
with radiotherapy after surgery. All participants received
10 mg/kg bevacizumab. Cumulative RO5323441 doses ranged
from 2.5 g to 60 g. Participants received a median of 8 doses
(range, 1–27 doses) of both RO5323441 and bevacizumab. Six-
teen participants discontinued the study due to progressive dis-
ease, one withdrew consent, and 2 patients discontinued the
study due to DLTs. Three other participants were withdrawn
by the investigator after complete metabolic responses on
18F-FDG PET scans after they had experienced objective ana-
tomic responses (2 complete responses, one partial response)
for up to 18 months while on study treatment. These partici-
pants were censored in PFS and OS analyses.
Safety
Two DLTs were reported in 2 participants. One participant ex-
perienced G3 meningitis associated with cerebrospinal fluid
(CSF) leak 12 days after the second dose of RO5323441
(1250 mg) and bevacizumab. This participant had undergone
surgery to resect the right uncus 1 month prior to first dose of
study drug. The epidural/subgaleal CSF leakage observed at
the time of meningitis was first noted 6 weeks previously,
and it was believed that bevacizumab might have caused or
compromised regression of preexisting CSF leakage that en-
hanced the risk of infection. The second DLT (G3 cerebral in-
farction) occurred 5 days after the first dose of combination
therapy (2500 mg RO5323441). No MTD was reached, and
the highest dose of RO5323441 tested was 2500 mg. Sixteen
(73%) participants died due to disease progression following
study discontinuation, whereas the remaining participants
were alive.
One hundred forty-six AEs were reported in 21 participants
(Table 2) including 31 G3/4 AEs (in 17 participants). Fifty-five
study drug-related AEs occurred in 20 participants including hy-
pertension (13 participants, 59%), dysphonia (11 participants,
50%), epistaxis (4 participants,18%) and fatigue (3 partici-
pants, 14%). The incidence and severity of AEs and drug-
related AEs were similar across dosing groups. Of the 21serious
AEs (SAEs) reported in 13 participants, only hypertension,
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Fig. 1. Effect of antiangiogenic treatment on DCE-MRI and DW-MRI parameters for the 6 participants (7 tumors) in the expansion cohort. DCE-MRI/
DW-MRI was performed twice at baseline and prior to any scheduled study drug on day 22 (2 weeks after the first dose of single-agent
bevacizumab), day 1, day 15, and days 53–55 (A). Overall relative change from baseline in median AUCBN (B) and individual profiles for the
relative change from baseline in median AUCBN (C), median ye (D), and median ADC (E) are indicated. Abbreviations: ADC, water diffusion
coefficient; AUCBN, area under the gadolinium concentration curve normalized with plasma input function; BL, baseline; DCE-MRI, dynamic
contrast-enhanced magnetic resonance imaging; DW-MRI, diffusion-weighted magnetic resonance imaging; PD, progressive disease; q2w,
once every 2 weeks; ye, fractional extracellular extravascular volume.
Table 1. Patient characteristics (N¼ 22)
Parameter RO5323441 Dose
625 mg (N¼ 4) 1250 mg (N¼ 6) 2500 mg (N¼ 12a) All (N¼ 22)
Sex, n (%)
Male 2 (50) 5 (83) 9 (75) 16 (73)
Female 2 (50) 1 (17) 3 (25) 6 (27)
Age, median (range) 60.0 (50–66) 58.0 (41–69) 57.0 (37–72) 58.0 (37–72)
Weight in kg, median (range) 73.0 (48.6–92.8) 83.5 (69.4–95.0) 75.0 (62.0–98.0) 79.5 (48.6–98.0)
BMI in kg/m2, median (range) 24.4 (18.8–26.3) 26.4 (22.7–31.3) 25.6 (20.0–31.4) 25.7 (18.8–31.4)
Corticosteroid use n (%) 2 (50) 3 (50) 11 (92) 16 (73)
Abbreviation: BMI, body mass index
aIncludes patients from both the dose-escalation (n¼ 6) and expansion cohort parts (n¼ 6) of the study.
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pulmonary embolism, confusion, and pneumonia occurred in
more than one participant. All SAEs of hypertension and pulmo-
nary embolism, meningitis associated with spinal fluid leak,
upper abdominal pain, and cerebral infarction were considered
to be study drug related. Four other SAEs were deemed possibly
related but unexpected.
There were no apparent dose-related changes in vital signs,
physical examinations, performance status, ECGs, or laboratory
parameters. All lower extremity ultrasounds were normal at
final visit.
Pharmacokinetics
Linear dose-dependent increases in peak and trough concen-
trations of RO5323441 were observed (Supplementary
Table S1). The PK parameters of RO5323441 were estimated
using a 2-compartment population PK model. The average ef-
fective half-life was 18.5+8.0 days, and the mean apparent
clearance was 0.19+0.05 L/day. The mean estimated volume
of distribution was 2.9+0.6 L for the central compartment and
2.1+1.5 L for the peripheral compartment. The mean area
under the concentration-time curve over the dosing interval
(AUCtau) at steady state was 4884+1142, 6075+1019, and
12762+3183 mg*day/mL for the 625, 1250, and 2500 mg
dose levels, respectively. The linear dose-exposure relationship
is shown in Supplementary Fig. S1). Bevacizumab serum expo-
sures were similar across cohorts and were unaffected by the
concomitant administration of RO5323441 (Supplementary
Table S2).
Pharmacodynamics
Following initial treatment with single-agent bevacizumab
(on day 214), DCE-MRI analysis revealed a large relative
decrease from baseline (60% by day 22) in initial area
under the gadolinium concentration curve normalized with
plasma input function (AUCBN). AUCBN is a composite parame-
ter that reflects flow, permeability, and vascular volume.23 This
Table 2. Adverse events of any grade reported by .10% of the study population and all G 3/4 events
Event Patients by Treatment Group and AE Grade (n [%])
625 mg (N¼ 4) 1250 mg (N¼ 6) 2500 mg (N¼ 12) All (N¼ 22)
AE leading to discontinuation 2 1 (17) 1 (8) 2 (9)
SAE 1 (25) 5 (83) 7 (58) 13 (59)
Any grade AE in .10% patients
Hypertension 3 (75) 3 (50) 8 (67) 14 (64)
Headache 3 (75) 4 (67) 5 (42) 12 (55)
Dysphonia 1 (25) 2 (33) 8 (67) 11 (50)
Fatigue 2 (50) 1 (17) 3 (25) 6 (27)
Nasopharyngitis – 1 (17) 4 (33) 5 (23)
Arthralgia – 2 (33) 2 (17) 4 (18)
Constipation 1 (25) 1 (17) 2 (17) 4 (18)
Epistaxis 1 (25) 1 (17) 2 (17) 4 (18)
Nausea – 1 (17) 2 (17) 3 (14)
All G 3/4 events
Hypertension 3 (75) 2 (33) 6 (50) 11 (56)
Headache 1 (25) – 1 (8) 2 (9)
Pneumonia – 1 (17) 1 (8) 2 (9)
Confusion 1 (25) 1 (17) – 2 (9)
Pulmonary embolism – 1 (17) 1 (8) 2 (9)
Fatigue – 1 (17) – 1 (5)
Deep vein thrombosis 1 (25) – – 1 (5)
Device-related infection – – 1 (8) 1 (5)
Meningitis associated with spinal fluid leak – 1 (17)a – 1 (5)
Sepsis – – 1 (8) 1 (5)
Tooth abscess – – 1 (8) 1 (5)
Urinary tract infection – – 1 (8) 1 (5)
Brain edema – – 1 (8) 1 (5)
Cerebral infarction – – 1 (8)a 1 (5)
Asthenia – – 1 (8) 1 (5)
Mucosal inflammation – – 1 (8) 1 (5)
Abdominal pain upper – – 1 (8) 1 (5)
aIndicates the 2 dose-limiting toxicities.
Abbreviations: AE, adverse event; G, grade; SAE, serious adverse event.
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effect (observed in all evaluated lesions in all participants) was
maintained for the duration of combination therapy (Fig. 1B
and C). A further decrease (day22 to day 1) occurred for 2 par-
ticipants after RO5323441 dosing. All participants also showed
amarked decrease (70% overall) in DCE-MRI-derived fraction-
al extracellular extravascular volume (ye; Fig. 1D). DW-MRI re-
vealed an overall smaller decrease (20%) in the water
diffusion coefficient (ADC), and a reduction in ADC was ob-
served in 4 of 6 participants (5/7 tumor lesions; Fig. 1E).
Baseline median plasma PlGF level (available for 21 partici-
pants) was 24.4 pg/mL (range, 14.1–31.3 pg/mL). In the expan-
sion cohort, the median baseline PlGF level was 25.5 pg/mL
(range, 20–31.3 pg/mL), which increased by40% after a single
dose of bevacizumab. In all cohorts, there was no apparent as-
sociation between baseline PlGF levels and clinical response. The
combined effect of bevacizumab plus RO5323441 on PlGF levels
could not be evaluated due to assay interference caused by
RO5323441.
Increases in VEGFA were observed following the administra-
tion of both combination therapy (cohorts 1–3) and bevacizu-
mab monotherapy (cohort 4; Fig. 2A). Following prolonged
combination treatment, the levels of VEGFA appeared to in-
crease to a greater extent with the highest tested dose of
RO5323441 (cohorts 3 and 4). Although results were variable,
decreased levels of FLT4 occurred following the administration
of both treatments (Fig. 2B).
Efficacy
Of the 22 treated participants, one (4.5%) participant had a
complete response, 4 (18.2%) had a partial response, 11
(50%) had stable disease, and 6 (27.2%) had progressive dis-
ease (Supplementary Table S3 and Fig. 3A). Two participants
experienced prolonged durable responses of 16 and 17 months
after treatment with 1250 mg and 625 mg RO5323441, re-
spectively. One participant had no on-treatment response as-
sessments and was therefore considered to have progressive
disease. These findings translate into an ORR of 22.7% and a
DCR of 72.7%. No dose-dependent effect was observed.
Median PFS was 3.5 months (95% CI, 2.6–4.3 months;
Fig. 3B) and median OS was 8.5 months (95% CI, 7.3–9.9
months; Fig. 3C). PFS-6 was 22.7%, and the Kaplan-Meier esti-
mate for 6-month OS was 81.8%.
Corticosteroid use decreased in 6 (38%) of 16 participants
who received corticosteroids at baseline (median dose reduc-
tion 250%; range, 220% to 280%).
Discussion
RO5323441 in combination with bevacizumab had acceptable
tolerability in participants with recurrent glioblastoma. Two
DLTs occurred, which led to participant withdrawal; however,
the MTD for the combination was not reached. The highest
RO5323441 dose tested was 2500 mg. The safety profile of
RO5323441 was similar across dose groups, and no participant
died while on the study. Hypertension was also the most fre-
quent treatment-related AE (64% of participants) but was
well managed with medication and did not lead to study dis-
continuations. The reason for the higher frequency of hyperten-
sion compared with previous studies with single-agent
RO532344119 (5%) or single-agent bevacizumab24 (30%–
40%; 4%–11% G3/4) remains unclear. This may reflect the
30%–50% higher RO5323441 exposure seen in this study com-
pared with that seen in patients with hepatocellular, ovarian,
and colorectal cancer treated with equivalent RO5323441
doses as monotherapy/combination therapy (Roche, unpub-
lished data). Conversely, bevacizumab exposure was not af-
fected by coadministration with RO5323441. Dysphonia,
Fig. 2. Effect of antiangiogenic treatment on plasma levels of VEGFA (A) and FLT4 (B). All participants received bevacizumab 10 mg/kg combined
with 625 mg (cohort 1), 1250 mg (cohort 2) or 2500 mg (cohorts 3 and 4) RO5323441 q2w. Combination dosing began on day 1 in cohorts 1–3. In
cohort 4 (expansion cohort) participants received single-agent bevacizumab on day 214 and day 1, single-agent RO5323441 on day 22, with
combination dosing beginning on day 15. Means of the relative change from baseline over time for each cohort are displayed. Abbreviations:
FLT4, fms-related tyrosine kinase-4; VEGFA, vascular endothelial growth factor A.
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which is uncommon with single-agent bevacizumab24 and
single-agent RO5323441,18,19 occurred frequently with combi-
nation therapy andmay indicate a synergistic toxicity; however,
all events were grade 1/2.
Consistent with the known antiangiogenic effects of bevaci-
zumab,25 VEGF inhibition was associated with a large decrease
in DCE-MRI AUCBN. Further reductions in AUCBN occurred in 2
participants following subsequent administration of RO532
3441, which may indicate an additive antiangiogenic effect.
The reductions in DW-MRI ADC and DCE-MRI ye reported here
are comparable to previous results with other antiangiogenic
treatments.15 This suggests that the 2 agents may be capable
of reducing vasogenic edema, a finding that has been
previously reported with bevacizumab.11,26 Bevacizumab ther-
apy can also decrease (peri-)tumoral edema in participants
with recurrent glioblastoma, thereby reducing the demand for
corticosteroids.27 This is consistent with the reduction in dexa-
methasone dose seen in 38% of participants who were receiv-
ing steroids at baseline in the current study.
Increases in plasma PlGF levels occur in patients with
glioblastoma treated with anti-VEGF therapies15,28 and may
represent an escape mechanism to antiangiogenic therapy.29
In this study, baseline plasma PlGF levels were comparable
with previous results15 and increased moderately following
bevacizumab administration. The influence of RO5323441 on
PlGF levels could not be assessed due to interference of
Fig. 3. Antitumor activity of RO5323441 and bevacizumab in glioblastoma patients. Waterfall plot showing maximum change in SLDs compared
with baseline (A) and Kaplan-Meier curves of progression-free survival (B) and overall survival (C) for all patients. Figure 3A shows the data for 19
participants because 2 participants had no target lesions, and one had no post-treatment tumor assessments. Tick marks on Kaplan-Meier curves
indicate censored data. Abbreviations: BOR, best overall response; CR, complete response; PD, progressive disease; PR, partial response; RANO,
Revised Assessment in Neuro-Oncology; SD, stable disease; SLD, summed longest tumor diameter.
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RO5323441with the assay. Across all cohorts, there was no ap-
parent association between baseline PlGF levels and clinical
response.
Bevacizumab therapy can increase levels of VEGF and
decrease levels of VEGFRs.30,31 PlGF has been proposed to stim-
ulate angiogenesis by displacing VEGF from the “VEGFR-1 sink,”
thereby increasing the fraction of VEGFA available to activate
VEGFR-2.32 Hence, neutralizing PlGF by escalating doses of
RO5523441 should decrease VEGFA levels by allowing in-
creased binding of VEGF to VEGFR-1. However, apparently
greater increase in VEGFA levels was seen in participants treat-
ed at the highest dose of RO5323441 (Fig. 2A), suggesting a
(over-) compensatory feedback mechanism of VEGFA express-
ing tumor cells. Moreover, increasing doses of RO5523441 may
also reduce the formation of PlGF/VEGF heterodimers,33 which
consequently increases VEGFA levels.
The ORR was 22.7% with no apparent differences between
RO5323441 dose groups (no formal comparison of RO5323441
dose level and efficacy was conducted due to the low number
of participants treated with the lower doses). Six-month PFS
was 22.7%, and median OS was 8.5 months. These results
are similar to previous findings with single-agent bevacizumab
in recurrent glioblastoma,10,11 including the recent BELOB34 and
CABARET35 studies (16%–24% PFS-6). While dual inhibition of
VEGFand PlGF did not increase the ORR compared with previous
studies of single-agent bevacizumab, 2 participants did experi-
ence durable responses of 16 and 17 months, respectively. The
value of PlGF as a therapeutic target in cancer remains undeter-
mined.36,37 Results with aflibercept, which binds both VEGFR
and PlGF, have also been disappointing in patients with glio-
blastoma (PFS-6 was 7.7%), despite the encouraging activity
of this agent in other cancers.38
In summary, the safety and tolerability of multiple-dose
RO5323441 and bevacizumab were acceptable and manage-
able, and the MTD for the combination therapy was not deter-
mined. While our study was not designed to test the efficacy of
RO5323441, the data suggest that dual anti-VEGF and
anti-PlGF inhibition with bevacizumab and RO5323441 in recur-
rent glioblastoma offers no therapeutic advantage over that
which can be achieved with bevacizumab alone. The clinical de-
velopment of RO5323441 has been terminated by the sponsor
following an overall portfolio review.
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